Purchase this article with an account.
S. D. Georgoulas, Q. Ru, D. Paull, L. Murray, S. Brocchini, P. T. Khaw; The Effects of Serum Amyloid P on Experimental Glaucoma Filtration Surgery. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3908.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To test the hypothesis that PRM-151 (recombinant human SAP) administration may inhibit scarring after GFS in an aggressive scarring model, and prolong bleb survival as well as IOP lowering compared to mitomycin-c (MMC) and no treatment. To also test whether SAP has any direct effect on fibroblast mediated collagen contraction in vitro.
A randomized, prospective, masked-observer study with 24 NZW rabbits undergoing modified GFS was conducted to evaluate the potential therapeutic effect of PRM-151 against fibrosis. Following GFS, local subconjunctival application of PRM-151 (2mg) alone or in combination with i.v. PRM-151 (5mg/kg) was performed. Sponges with 0.2mg/ml MMC and with sterile water served as positive and negative controls, with eyes also receiving local PBS on the same dosing schedule as PRM-151. Eyes were harvested at the end of the 30-days after GFS and histological analysis was performed.
PRM-151 administration in vivo significantly prolonged bleb survival (<0.01 Log Rank) in comparison to both positive and negative control groups. There was no overt increase in inflammation or other local side effects. Both PRM-151 groups had statistically significantly lower IOP than the water sponge (WS) and MMC groups at day 30 and lower collagen deposition and cellularity compared to the MMC and the WS groups.
The results of this study indicate that PRM-151 administration results in a reduction in scarring following experimental GFS and may be a potential therapeutic agent.
This PDF is available to Subscribers Only